VS-5584 (also known as defactinib) is a small molecule drug developed by Verastem Oncology for the treatment of various types of cancer. It is currently in clinical trials and has shown promising results in preclinical studies.
Chemical name: The chemical name of VS-5584 is N-(2,5-difluorophenyl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl) benzenesulfonamide.
Molecular formula: The molecular formula for VS-5584 is C19H20F5N3O2S.
Formula weight: The formula weight for VS-5584 is 463.45 g/mol.
CAS No: The CAS number for VS-5584 is 1246560-33-7.
Top Ten Keywords and Synonyms:
Synonyms: Defactinib; VS5584; VS 5584; VS-5584 hydrochloride; N-(2,5-Difluorophenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzenesulfonamide; Verastem Oncology Compound 106
Health Benefits of VS-5584: VS-5584 is designed to inhibit a protein called focal adhesion kinase (FAK), which plays a role in cancer cell survival, migration, and invasion. By inhibiting FAK, VS-5584 may help to slow or stop the growth of cancer cells, potentially leading to tumor regression and improved patient outcomes.
Potential Effects of VS-5584: Preclinical studies have shown that VS-5584 can inhibit the growth and metastasis of various types of cancer cells, including breast, lung, and pancreatic cancer cells. Additionally, VS-5584 has been shown to sensitize cancer cells to chemotherapy and radiation therapy, potentially enhancing their efficacy.
Product Mechanism: VS-5584 works by targeting and inhibiting the activity of FAK, a protein that plays a key role in the regulation of cell adhesion, migration, and invasion. FAK is overexpressed in many types of cancer cells, making it an attractive target for cancer therapy. Inhibition of FAK by VS-5584 leads to reduced cancer cell survival, migration, and invasion, potentially slowing or stopping the growth and spread of tumors.
Safety: As with any new drug, the safety of VS-5584 is being carefully evaluated in clinical trials. Preliminary studies suggest that VS-5584 is generally well-tolerated, with manageable side effects.
Side Effects: Common side effects of VS-5584 include fatigue, nausea, vomiting, and diarrhea. Less common but more serious side effects may include low white blood cell count, liver damage, and heart problems.
Dosing Information: The appropriate dose of VS-5584 depends on several factors, including the patient's age, weight, and overall health status. Dosage and duration of treatment are determined by the treating physician.
Conclusion: VS-5584 (defactinib) is a promising new drug under investigation for the treatment of various types of cancer. By inhibiting the activity of the FAK protein, it has the potential to slow or stop the growth and spread of tumors, potentially improving patient outcomes. While the drug is still in clinical trials, preliminary studies suggest that it is generally well-tolerated with manageable side effects. As research continues, VS-5584 may represent an exciting new option for patients with cancer
